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Human studiesAutophagy, a cellular housekeeping process, is essential tomaintain tissue homeostasis, particularly in long-lived
cells such as cardiomyocytes. Autophagic activity declineswith age andmay explainmany features of age-related
cardiac dysfunction. In this review we summarize the current state of knowledge regarding age-related changes
in autophagy in the heart. Recent ﬁndings from studies in human hearts are presented, including evidence that
the autophagic response is intact in the aged human heart. Impaired autophagic clearance of protein aggregates
or deteriorating mitochondria will have multiple consequences including increased arrhythmia risk, decreased
contractile function, reduced tolerance to ischemic stress, and increased inﬂammation; thus autophagy repre-
sents a potentially important therapeutic target to mitigate the cardiac consequences of aging. This article is
part of a Special Issue entitled CV Aging.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
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Autophagy is the process that maintains cellular homeostasis
through the renewal/recycling of cytoplasmic materials, organelles
(such as mitochondria), removal of aggregated proteins, and theChair in Molecular Cardiology,
SP9105, Los Angeles, CA 90048,
eb).
. This is an open access article underprovision of energy and biomolecules to cells [1]. Autophagy has been
demonstrated to play an important role in an array of age-related dis-
eases, contributing to diseases such as neurodegenerative and muscle
disorders, cancer, cardiovascular disease, metabolic syndrome, obesity,
as well as infection and inﬂammation [2–11] and many, many others.
2. Autophagy machinery
Autophagy is characterized by the delivery of intracellular compo-
nents to the lysosome, which can be accomplished via three differentthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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types [12]: microautophagy, chaperone-mediated autophagy, and
macroautophagy. Microautophagy is a constitutive process by which
random invaginations in the lysosomal or vacuolar (plants) membrane
deliver cytoplasm to the lysosomal lumen via singlemembrane vesicles,
resulting in the degradation of cytoplasmic material [13–15]. The
microautophagy pathway is important during nutrient starvation
[15] targeting glycogen to the lysosome [16], and selective degradation
of peroxisomes, mitochondria, and parts of the nucleus (yeast) [13].
Chaperone-mediated autophagy (CMA) is characterized by lysosomal
targeting, translocation across the lysosomal membrane, and subse-
quent degradation of speciﬁc, predominantly cytosolic proteins con-
taining a pentapeptide motif biochemically related to KFERQ [17]. A
process solely identiﬁed in mammals, CMA does not require the forma-
tionof amembrane; instead, a cytosol-borneheat shock cognate protein
of 70 kDa, Hsp70, binds the target, and ferries it to a complex consisting
of LAMP2A (Lysosome-associated Membrane Protein 2A) and Hsp90
embedded in the lysosomal membrane, promoting protein unfolding
[18]. The LAMP2A complex multimerizes and threads the protein into
the lysosomal lumen where the protein is destroyed. CMA is thought
to be constitutive in most cell types in order to maintain homeostasis
by clearing non-functional proteins. It has been shown to respond to
starvation (although its response is somewhat delayed compared to
macroautophagy [19]) and increased reactive oxygen species (ROS)
levels [20] and has been shown to decline with age [21–23]. Finally,
macroautophagy is a form of autophagy that relies on the de novo for-
mation of a double membrane vesicle (autophagosome) around the
cargo to bedegraded. This constitutive process has been shown to great-
ly increase in times of stress, e.g. starvation [24], myocardial ischemia
[25], and infection [9]. Of the three autophagy pathways, macroa-
utophagy is the best characterized and is discussed in greater detail
below.
The macroautophagy pathway consists of 36 identiﬁed proteins of
which 16 are considered essential elements of the core machinery
[26]. There are a variety of excellent reviews of the autophagy pathway
and its regulation [1,27,28]. The initiation of autophagy is accomplished
through the inactivation of mammalian target of rapamycin (mTOR)
[27,29]. mTOR maintains ULK1 (human homologue of Atg1 in yeast)
in the phosphorylated form (pULK1-Ser-757) that prevents it from
initiating autophagy [27]. Autophagy-inducing stimuli release mTOR
repression of ULK1, allowing it to activate the Beclin-1 complex [30].
The Beclin-1 complex in addition to other autophagy proteins assist in
phagophore nucleation and the recruitment of proteins associated
with phagophore elongation [30,31]. The origin of the membrane is
still being elucidated, however, it appears that the ER (the primary
site of autophagosome assembly) [32–34], the mitochondrial mem-
brane [35], and the plasma membrane [36] are the likely sources.
Elongation of the phagophore requires ubiquitin-like conjugation
systems that help to convert LC3 into the LC3-II form that is incorporat-
ed in the autophagosomal membrane. One system utilizes Atg7 and
Atg10 to create the irreversible covalent linkage between Atg5 and
Atg12, which then associates with Atg16L1 to form a complex required
for membrane elongation [27]. A second ubiquitin-like conjugating sys-
tem is required for the incorporation of LC3-II into the autophagosomal
double membrane [27]. Atg4 cleaves the terminal amino acid(s) from
LC3, yielding LC3-I. The activities of the ubiquitin-like proteins
Atg3 and Atg7 in conjunction with or without the Atg5–12–16L1 com-
plex facilitate the addition of phosphatidylethanolamine to LC3-I,
resulting in LC3-II and subsequent incorporation of LC3-II into the
autophagosomal membrane [27,37]. LC3-II is incorporated into both
faces (convex and concave) of the cup-shaped phagophore double-
membrane structure [27]. Upon formation of the autophagosome,
Atg5–Atg12–Atg16L1 dissociates from the autophagosomal double-
membrane and LC3-II is recycled from the outer leaﬂet and converted
to LC3-I again by Atg4 (LC3-II incorporated into the inner leaﬂet is even-
tually degraded by lysosomal hydrolases following autophagosome–lysosome fusion) [27]. The autophagosomes can fuse with other
autophagosomes, with endosomes (amphisome), or with lysosomes
(autolysosome or autophagolysosome) [38].
LAMP2 isoforms expressed on the lysosomal surface mediate
fusion with the autophagosome resulting in formation of the
autophagolysosome. Lytic lysosomal enzymes catalyze the degrada-
tion of the inner autophagosomal membrane along with its protein/
organelle cargo [27]. In order to target speciﬁc substrates for degrada-
tion, the autophagy system relies on a handful of adapter proteins of
which p62/SQSTM-1 is the best characterized in the context of targeting
protein aggregates to the autophagy pathway [39]. P62 possesses do-
mains for binding both LC3 and ubiquitin, meaning that it binds
ubiquitinated substrates and targets them to the autophagy pathway
via its LC3 binding domains [40]. Therefore, if the autophagic pathway
is functioning normally, levels of p62 and ubiquitin-tagged proteins
should not increase. Since the role of p62 in autophagy is aggregate
association, studies of p62 require differential analysis of detergent-
soluble and detergent-insoluble protein fractions [39]. P62 also serves
as an important adaptor protein for mitochondria whose outer mem-
brane is tagged with ubiquitin [41] by Parkin [42] or other ubiquitin li-
gases such as MULAN [43].
3. Role of autophagy in longevity in animal models
Autophagy functions in a cytoprotective role through the removal of
toxic protein aggregates, damagedmitochondria andharmful reactive ox-
ygen species, intracellular infectious pathogens, etc. Autophagy not only
contributes to cell survival but is involved in organismal lifespan. The as-
sociation between autophagy and lifespan extension was ﬁrst noted by
brain-speciﬁc overexpression of Atg8a in Drosophila melanogaster [44]
and later, by general overexpression of Atg5 in mice [45]. These proteins
are essential for autophagosome formation and overexpression was
found to not only extend median lifespan but also promote anti-aging
phenotypes, including leanness, increased insulin sensitivity, and im-
proved motor function. Although several manipulations may lead to life
extension, a common denominator is their association to autophagy
[46]. Importantly, these interventions have been shown to extend to
many animal species. Several conserved genes that have been shown to
increase lifespan, e.g., sirtuin 1, also induce autophagy. Rapamycin, a phar-
macological inducer of autophagy, inhibits TORC1 (target of rapamycin
complex 1) and prolongs lifespan in several organisms, as does caloric re-
striction [47–49].
Both sirtuin1 and rapamycin promote lifespan under conditions in
which autophagy is induced [50–52]. Sirtuin 1 is a conserved NAD+
dependent histone deacetylase that affects major regulators of autoph-
agy (e.g., AMP-dependent kinase [AMPK]) and autophagy-related gene
products (e.g., Atg5, Atg7, Atg8) [53]. It was shown that deletion of
Beclin-1 (Atg6) not only suppressed the induction of autophagy by
sirtuin 1 expression but it also abrogated the effect of sirtuin 1 in extend-
ing lifespan [50]. Lifespan extension by rapamycin was inhibited
through deletion or silencing of Atg1, Atg7 or Atg5 [51,52]. It should
be noted that although many ﬁndings, such as these, support a linkage
between autophagy and lifespan, many of the essential regulators of
autophagy that have been shown to demonstrate this relationship
(e.g., Beclin-1) may also function in other homeostatic cellular path-
ways. Thus, longevity may not be solely dependent on autophagy.
4. Autophagy in the heart in animal models of aging
One of the preeminent damaged-based theories of aging that is
applicable to the heart involves cellular damage associated with cumu-
lative damage from ROS [54,55]. The highmetabolic activity of the heart
is supported by a large population of mitochondria and a steady supply
of oxygen. Moreover, cardiomyocytes are replaced infrequently [56],
making them ideal candidates for oxidative damage and stress with
the passage of time [57,58]. Dysfunctional mitochondria are a known
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related accumulation of dysfunctional mitochondria (and the ROS they
generate) is due to a reduction in autophagy (speciﬁcally mitophagy)
[57,59]. As a result, dysfunctional mitochondria accumulate as the
cells age, presumably due to the loss ofmitophagy, and promote the for-
mation of ROS, which negatively modiﬁes DNA, proteins, membranes,
and organelles, leading to further accumulation of damaged
mitochondria and ROS creating a positive feedback loop that results in
the “aging” phenotype with a decline in mitophagy/autophagy at its
core [55,57,60,61]. There are several lines of evidence that suggest that
this is possible.
First, it is well established that as the heart ages, basal ROS levels in-
crease [58] and a large number of mitochondria from aged post-mitotic
cells are enlarged and typically suffer from a loss of function and turn-
overmechanisms, i.e. ﬁssion, fusion, protein quality control, and remov-
al by autophagy (reviewed by Terman et al. [62]). Second, autophagy,
and by extension mitophagy, has been shown to be a vital component
of cellular homeostasis by degrading dysfunctional mitochondria, thus
limiting ROS production and making the study of autophagy relevant
to many cardiovascular diseases, e.g. ischemia/reperfusion injury [63].
Third, ROS have been shown to induce autophagy in vitro via AMPK ac-
tivation [64] and/or by regulating Atg4 activity in vitro [65], establishing
that the cellular response to ROS involves autophagy, likely as a mecha-
nism to limit further ROS production from damaged mitochondria and
potentially as a means to eliminate oxidatively damaged organelles
and protein aggregates. Fourth, a cardiac-speciﬁc deletion of the au-
tophagy protein, Atg5, resulted in an age-related accumulation of ab-
normal or “collapsed mitochondria,” a decline in respiratory function,
and a decrease in mitochondrial removal, indicating that autophagy is
vital to preserve cardiac function in the aged [66]. Finally, interactions
between ROS and iron-containing macromolecules have been shown
to promote the formation and accumulation of an intralysosomal aggre-
gate, lipofuscin, as cells age (a well described hallmark of aging) [61,62,
67,68]. Lipofuscin is indigestible, contributes to dysregulation of
lysosomal pH, and possibly prevents/limits autophagy by disrupting
lysosome/autophagosome fusions. Taken together, these studies
demonstrate a link between autophagy, ROS, and aging with an age-
related dysregulation of autophagy at its core.
It is generally accepted that autophagy declines with age, based
on indirect evidence provided by the lipofuscin and ROS studies in
the aged heart [62,66,67,69–75]. However, to get a clear indication of
how autophagy is manifest in the aging heart, the autophagy pathway
must be interrogated directly. Autophagy is commonly measured by
western blotting for LC-II [76], in which it is generally accepted that
an increase in LC3-II is associated with an increase in autophagy
(although increased LC3-II could also result from impaired autophagic
ﬂux). Studies of autophagy in the aging heart have yielded inconsistent
results. For example, Inuzuka et al. demonstrated that LC3-II remains
constant when comparing 3 to 20–24 month old FVB mice [74]. Addi-
tionally, Taneike et al. showed that LC3-II levels decline when compar-
ing 2.5 mo and 26 mo C57BL/6 mice [66]. Conversely, Boyle and
colleagues showed an increase in LC3-II and Beclin-1 levels when com-
paring 2 mo and 18 mo C57BL/6 mice [72]. Finally, Wohlgemuth et al.
[71] compared 6 mo and 26 mo Fisher 344 rat hearts and showed an
age-related increase in Beclin-1, LC3-I, LC3-II, no change in Atg7, and a
decline in Atg9. The inconsistencies in the data could be due to differ-
ences in mouse strain or species, ages of the animals being compared,
conditions under which the animals were maintained, or even time of
day at which tissues were harvested. As reviewed elsewhere [161],
measurement of autophagic ﬂux would be more informative than
“snapshot” LC3-II levels. In our unpublished studies of C57BL/6mice, au-
tophagic ﬂux is impaired in aged mice (24 mo vs 3 mo). Consequently,
morework needs to be done to characterize how autophagy in the heart
changes with age and how those speciﬁc changes are manifest.
Autophagic clearance of mitochondria is important for maintenance
of mitochondrial function, limitation of ROS production, and as aprerequisite for mitochondrial biogenesis. Impaired mitochondrial bio-
genesis is recognized as an early event in heart failure [77], and is a fea-
ture of cardiac aging [78]. Overexpression of Parkin, a ubiquitin ligase
important for mitochondrial turnover, ameliorated the age-related de-
cline in cardiac function [78], whereas Parkin deﬁciency results in accu-
mulation of abnormal mitochondria, particularly after injury [79].
Preservation of mitochondrial integrity is important not only for ATP
production and calcium homeostasis necessary for contractile function
and stable electrical conduction, but also to limit ROS production and in-
ﬂammation. Thus impairedmitochondrial clearance through autophagy
will have multiple consequences including increased arrhythmia risk,
decreased contractile reserve, reduced tolerance to ischemia/reperfu-
sion injury, and increased inﬂammation. Similar events and cross-talk
with endothelium and smoothmuscle will result in accelerated athero-
sclerosis and vasoconstriction [Fig. 1].
5. Impact of aging on autophagy and inﬂammation
The maintenance of homeostasis is dependent upon the recognition
of environmental changes aswell as exposure to insult. “Danger-associ-
atedmolecular patterns” (DAMPs), such asROS,mitochondrial DNAand
extracellular ATP, are detected by “pattern recognition receptors”
(PRRs) that are comprised of several families, including “Toll-like recep-
tors” (TLRs) and “Nod-like receptors” (NLRs). These molecules are not
only involved in innate and adaptive immune responses, but they
have been implicated in the control of autophagy and vice versa.
DAMPs shown to activate the NLRP3 inﬂammasome include extra-
cellular ATP [80], cholesterol crystals [81,82], hyaluronan [83], calcium
phosphate crystals [84], amyloid-β [85], and ROS. In spite of the number
of physically and chemically diverse stimuli that have been shown to
activate the NLRP3 inﬂammasome, three non-exclusive butwidely sup-
ported models by which the inﬂammasome is activated have been pro-
posed [86]. These include extracellular ATP, lysosomal disruption, and
ROS induction. During cell death, high concentrations of extracellular
ATP have been shown to mediate intracellular potassium depletion
and induce IL-1β secretion [87]. Extracellular ATP stimulates the
purinergic P2X7 ATP-gated ion channel [88] triggering potassium efﬂux
and inducing gradual recruitment of the pannexin-1 membrane pore
[89]. Pore formation allows extracellular NLRP3 agonists to access the
cytosol and directly activate NLRP3. The second model involves activa-
tors that form crystalline or particulate structures. These molecules
disrupt lysosomes causing lysosomal particles/contents to leak into
the cytosol and activate the NLRP3 inﬂammasome [90]. In the third
model, elevated ROS is observed upon treatment with NLRP3 activators
[91,92]; as such, it has been proposed that this common pathway en-
gages the NLRP3 inﬂammasome.
Autophagy and inﬂammation are interdependent processes [93].
Cells with defects in autophagy accumulate damaged mitochondria
and present increased levels of ROS, which results in increased levels
of inﬂammatory cytokines. The production of IL-1β is dramatically
affected by autophagy. Processing of pro-IL-1β into its active form de-
pends on the assembly of inﬂammasomes, and increased ROS levels
seem to be a prerequisite for inﬂammasome activation. Inﬂammasomes
are multimeric protein complexes that are comprised of a “sensor NLR”
and function as platforms for the activation of pro-caspase-1, resulting
in the processing and secretion of IL-1β and IL-18.
NLRP3 is one of several sensors but is unique in that it is activated by
awide array of host-derived and exogenous agonists.Mitochondria play
an important role in the activation of the NLRP3 inﬂammasome [94,95].
Nakahira et al. [94] showed a role for mitochondrial DNA in the activa-
tion of the NLRP3 inﬂammasome while Zhou et al. [95] demonstrated
the critical role formitochondrial ROS. Shimada et al. [96] demonstrated
that during programmed cell death cytosolic release of oxidized
mitochondrial DNA binds to and activates the NLRP3 inﬂammasome
to generate IL-1β. Failure to clear damaged mitochondria through the
autophagic pathway may lead to increased opportunities for release of
Fig. 1. The cardiac unit in abnormal homeostasis. In the setting of advanced age, rate-limiting autophagy factors (e.g., Atg5 and LC3) are downregulated and ﬂux is impaired. Excess insulin
signaling and/or nutrient excess suppresses autophagy at transcriptional and post-translational levels. Loss of normalmitochondrial turnover results in the accumulation of mitochondria
with distinctive oxidativeposttranslationalmodiﬁcations including oxidizedmitochondrialDNA (8-oxodGmtDNA). Reactive oxygen species (ROS) from thesedysfunctionalmitochondria
drive NFκB signaling in cardiomyocytes and endothelial cells, and support inﬂammasome assembly in competent cell types (endothelial cells, tissue macrophages). The inability to clear
damagedmitochondria in the setting of ischemic stress will abrogate cardioprotective interventions, while increased inﬂammatory signalingwill exacerbate postinfarction remodeling, in
part through stimulation of ﬁbroblast proliferation. Upregulating autophagy restores homeostasis.
Fig. 2.Mitochondrial damage and inﬂammasome activation. Mitochondrial damage leads to increased ROS production and oxidative damage to mtDNA. Damaged mitochondria are or-
dinarily cleared via mitophagymediated by PINK1/Parkin/p62, but if mitophagy is impaired by overnutrition or advanced age, thenmtDNAwith 8-oxo-dGmodiﬁcationsmay be released
into cytosol, where it can interact with TLR9 and the NLRP3 inﬂammasome to trigger IL-1 beta synthesis and processing.
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IL-1β requires two signals: 1. The production of the inactive pro-IL-1β
form is mediated by TLR and consequent NFκB activation; 2. The pro-
cessing of pro-IL-1β to its mature IL-1β form requires the formation of
the NLRP3 inﬂammasome and activation of caspase-1. Importantly,
the activation of theNLRP3 inﬂammasomenot only leads to IL-1β secre-
tion but it can induce caspase 1-dependent cell death or pyroptosis, a
highly inﬂammatory form of cell death characterized by both apoptosis
and necrosis [97]. This can further exacerbate inﬂammation through the
release of DAMPs.
Autophagy has been shown to regulate the magnitude of inﬂam-
mation. Interventions including the use of autophagy inhibitor 3-
methyladenine (3-MA), deletion of LC3B or ATG16L1, silencing of
Beclin-1, or dominant negative forms of the cysteine protease ATG4B
lead to signiﬁcantly higher levels of IL-1β [94,98–100]. Autophagy con-
trols inﬂammasomes by targeting its components to autophagosomes.
It has been shown that pro-IL-1β is delivered to autophagosomes after
TLR stimulation [98] and that NLRP3 inﬂammasomes containing ASC
are directed to autophagosomes through ubiquitination [100].
Although it is known that autophagy declineswith age, whether this
leads to the increase in basal levels of inﬂammation, i.e., inﬂamm-aging,
has yet to be determined. However, recentwork by Dixit and colleagues
suggests that the activation of the NLRP3 inﬂammasome causes global
age-related inﬂammation in multiple organs, with consequences such
as thymic demise, impaired glycemic control, reducedmemory and cog-
nition, deterioratingmotor performance, and bone loss [101]. Inﬂamm-
aging is associatedwithmany age-associated diseases, including cardio-
vascular disease. It is known that inﬂammation is a key process in the
mediation of myocardial damage and repair post MI (reviewed in
[102]). Previous studies have shown that targeting the inﬂammatory
response improves MI outcome (reviewed in [103,104]). The neutraliz-
ing antibody against IL-1β and Anakinra, a recombinant IL-1 receptor
antagonist, was shown to exert beneﬁcial effects on acute MI in young
animals [105,106]. Kawaguchi et al. [107] demonstrated a role for
inﬂammasomes duringmyocardial I/R injury using ASC-knockout (apo-
ptosis-associated speck like protein: a scaffolding component of several
inﬂammasomes, including the NLRP3 inﬂammasome) and caspase-1
knockout mice. They found the formation of inﬂammasomes post I/R
as indicated by the detection of ASC in inﬁltrated neutrophils and mac-
rophages as well as in vascular cells and cardiac resident ﬁbroblasts.
Furthermore, they found a signiﬁcant decline in inﬂammatory cell
inﬁltration and cytokine/chemokine expression as well as a signiﬁcant
reduction of infarct size, myocardial ﬁbrosis, and left ventricular
dysfunction after MI in the ASC- or caspase-1-knockout mice. In bone
marrow (BM) transplantation experiments (i.e., BM WT → WT, BM
ASC−/−→WT, and BMWT→ ASC−/− chimeras), Kawaguchi et al. ob-
served a reduction in infarct size following I/R in chimeras that lacked
ASC in hematopoietic cells or non-hematopoietic cells suggesting the
importance of inﬂammasomes in bone marrow derived inﬂammatory
cells aswell as in residentmyocardial cells, i.e., cardiomyocytes and car-
diac ﬁbroblasts.
Using a murine model of permanent MI, Mezaroma et al. [108] re-
ported that cardiomyocytes formed NLRP3 inﬂammasomes and that
its activation induced caspase-1 dependent cardiomyocyte cell death,
pyroptosis, but not IL-1β release. Importantly, they showed that inhibi-
tion of NLRP3 and the P2X7 receptor by small interfering RNA or a phar-
macological inhibitor prevented inﬂammasome activation and cardiac
cell death, and reduced remodeling post MI. P2X7 is a purinergic recep-
tor ion channel that is activated by extracellular ATP released from
injured cells, leading to potassium efﬂux and subsequent NLRP3 activa-
tion [80]. Using mouse and rat permanent MI models, Sandanger et al.
[109] demonstrated that ﬁbroblasts of the ischemicmyocardiumupreg-
ulate NLRP3 and secrete IL-1β in response to extracellular ATP released
from damaged tissue. Langendorff-perfused hearts from NLRP3 knock-
out mice had preserved myocardial function and reduced infarct size
after I/R compared to hearts isolated from wild type and ASC knockoutmice. Although further analysis is needed to understand the basis for
the difference in NLRP3 vs ASC knockouts, it is clear that the NLRP3
inﬂammasome exacerbates ischemic injury. Contrary to these ﬁndings,
Zuurbier et al. [110] showed no improvement in either cardiac function
or cell death in response to I/R in Langendorff-perfused hearts isolated
fromNLRP3 knockout mice. The reasons for the discrepancy are unclear
but are discussed elsewhere [111,112]. Taken together, the data suggest
that cardiomyocytes and cardiac ﬁbroblasts function in different roles
(ﬁbroblasts secrete IL-1β whereas cardiomyocytes do not secrete IL-
1β but undergo pyroptosis), which contribute to cardiac inﬂammation
and remodeling in MI.
Although a growing body of evidence indicates that the NLRP3
inﬂammasome-driven inﬂammatory responses contribute to the patho-
physiology of MI, no reagents that speciﬁcally target NLRP3 are avail-
able. It should also be noted that despite the abundant literature on
the NLRP3 inﬂammasome in monocytes/macrophages during inﬂam-
mation, its contribution to myocardial ischemia/reperfusion injury is
still emerging. Changes that may occur with aging or the role of autoph-
agy in potentially regulating this process remain to be studied.6. Autophagy in the human heart
Autophagy as an adaptive response to stress is undergoing intense
investigation in an assortment of cellular and animalmodels. The grow-
ing interest in clinical relevance is not surprising given the increase in
incidence and prevalence of neurodegenerative and cardiovascular
diseases worldwide and the preclinical evidence suggesting that loss
of adaptive autophagy is a common contributing factor. Dysfunctional
or impaired autophagy has also been implicated in the exaggerated
inﬂammatory process associated with type 2 diabetes and aging [113].
Delineating the role of impaired autophagy in human disease is com-
plicated by our limited ability to measure it. Examination of autophagic
activity requires access to fresh tissue for western blot analysis, immu-
noﬂuorescence microscopy, and/or electron microscopy. Nevertheless
we do have some hints that cardiac autophagy is an active process in
patients.
One of the ﬁrst studies to suggest that autophagy is an adaptive
process in the human heart was the report by Kassiotis et al [114].
Paired biopsies of the left ventricle were obtained from 9 patients
with idiopathic dilated cardiomyopathy who were supported with a
left ventricular assist device (LVAD). Biopsies were obtained at the
time of implantation and removal of the LVAD. These investigators ob-
served a downregulation in mRNA and protein levels of autophagy
genes after prolonged support. They concluded that autophagy is an
adaptive mechanism in the failing heart and is attenuated with circula-
tory support.
In 2012 Garcia et al. studied 170 patients who had undergone elec-
tive coronary artery bypass surgery (CABG) and pre-operatively were
in normal sinus rhythm [115]. During the operation right atrial biopsies
were obtained for evaluation of remodeling by light and electron mi-
croscopy. Systemic inﬂammatory markers were measured at baseline
and 72 h after surgery. Protein ubiquitination and autophagy-related
LC3B proteins were assessed by western blot. The investigators
observed that 22% of the patients developed postoperative atrialﬁbrilla-
tion (POAF) and the level of high-sensitivity C-reactive protein, ﬁbrosis,
inﬂammation,myxoid degeneration, and ubiquitin-aggregateswas sim-
ilar between patients with and without POAF. Electron micrographs,
however, showed an accumulation of autophagic vesicles and lipofuscin
deposits in the biopsies of the patients with POAF. While the total
protein ubiquitination was similar in the patients with and without
POAF, LC3B processing was markedly reduced in those with POAF, sug-
gesting a selective impairment in autophagic ﬂux. The authors conclud-
ed that ultrastructural changes consistent with impaired autophagy
were present in atrial biopsies of patients that developed POAF after
CABG.
Table 1
Characteristics of 38 cardiac surgery patients.
Variable Average
Age (years) 62 ± 13
Males (%) 87%
BMI (kg/m2) 31 ± 6
Dyslipidemia 79%
HbA1c (mean %) 6.6 ± 1.8
Previous MI (%) 40
Ejection fraction (%) 53 ± 8.7
Aortic cross-clamp time (min) 108 ± 40







49P.-J. Linton et al. / Journal of Molecular and Cellular Cardiology 83 (2015) 44–54In 2010, our group initiated work on a translational research project
to study the homeostatic intracellular repair response (HIR2), a clinical
term used to characterize adaptive autophagy in the human heart. The
Wayne State University Institutional Review Board (IRB) approved all
the protocols which involve human subjects. In patients undergoing
heart surgery with cardiopulmonary bypass (CPB), we collected a
small amount of right atrial tissue (100 to 200 mg) at two time points:
before initiation of CPB and aortic cross-clamping; and after removal
of cross-clamp andweaning fromCPB. Autophagic activitywas assessed
by western blot analysis of a variety of molecular markers.
In 2013, we (Jahania et al.) reported the results from the initial 19
patients regarding the effects of cardiac stress on theHIR2 [116].We ob-
served that ischemic stress was associated with a signiﬁcant depletion
of Beclin-1, ATG 5–12, LC3-II and p62. The difference in p62 levels mea-
sured at the time of aortic crossclamping and subsequent weaning from
CPB correlated signiﬁcantly with changes in Beclin-1, Atg5–12, LC3-I
and LC3-II [116]. These ﬁndings point to a coordinated engagement of
the autophagy machinery during cardiac stress and the depletion of au-
tophagy proteins was interpreted to reﬂect increased autophagic ﬂux.
This interpretation, however, depends upon two assumptions: (1) the
decrease in autophagy proteinswas due to lysosomal (not proteasomal)
degradation and (2) protein synthesis was generally suppressed during
CPB.
The ﬁndings in the Jahania study are consistent with the report by
Singh et al. [117]. These investigators examined patients undergoing
heart surgery and obtained samples from right atrial appendages before
cardioplegic arrest and after reperfusion. Tissuewas submitted for poly-
merase chain reaction (PCR) array, quantitative real-time PCR, and
immunoblot analysis for autophagy proteins and their associated up-
stream regulators. In this study, ischemia/reperfusion was associated
with upregulation of 11 (13.1%) and downregulation of 3 (3.6%) of 84
autophagy related genes (ATG). Speciﬁcally, there were increases in
ATG4A, ATG4C, ATG4D, and GABARAPL2. This study is important be-
cause it provides information on both mRNA and protein, a limitation
of the other human studies. Autophagic activity was conﬁrmed through
observations of higher LC3-I levels and an increase in the LC3-II/LC3-I
ratio. As expected, the activation of autophagy was accompanied by
phosphorylation of AMPK and dephosphorylation of mTOR. They con-
cluded that gene expression and post-translational regulation of
autophagy in the human heart are affected by ischemia/reperfusion
and went on to speculate that the ﬁndings could lead to autophagy-
targeted therapeutic approaches to limit cardiac injury.
In contrast to the evidence that cardiac autophagy is activated in
humans in response to ischemia/reperfusion, Gedik et al. [118] reported
that autophagywas not associatedwith protection conferred by remote
ischemic preconditioning (RIPC) in patients undergoing CABG surgery.
In this study, left ventricular biopsies were available from 20 CABG pa-
tients (10 RIPC and 10 placebo patients) who were previously enrolled
in a large randomized, prospective, double-blind, placebo-controlled
study evaluating the efﬁcacy of RIPC in conferring intraoperative myo-
cardial protection. Transmural myocardial biopsies of the left ventricle
from the territory undergoing revascularizationwere taken before initi-
ation of cardiopulmonary bypass (CPB) and at 5–10 min reperfusion.
The investigators failed to observe differences in the abundance of
key autophagy proteins either with ischemia/reperfusion or between
the placebo and RIPC cohorts despite evidence of RIPC-induced protec-
tionmanifest as a reduction in serum cTnI. There were important differ-
ences however between this study and the one reported by Jahania et al.
The sample sizewas smaller, biopsies were taken from the left ventricle,
the duration of ischemia/reperfusion was shorter, and paired analysis
was not reported. In the Jahania study, each patient's paired before
and after ischemia resultswere reported as a delta value after normaliz-
ing to actin. Actinwas chosen because it is less subject to acutemetabol-
ic changes compared to themetabolic enzymeGAPDHused in the Gedik
study. The Gedik study reported themean baseline (before cross clamp)
compared to the mean value at 10 min reperfusion, and may havemissed individual pre-post changes. Another possible explanation for
the failure to detect changes in autophagy proteins in these left
ventricle samples is that they were from a region of the heart that was
ischemic even at baseline; it might have been impossible for the
already-ischemic tissue to further upregulate autophagy in response
to the added stress of CPB. Nevertheless, this study, which is the only
one to examine left ventricle in human patients, raises concern that dif-
ferences in autophagymay exist between atria and ventricles.While the
majority of observations to date suggest that cardiac autophagy is an ac-
tive and adaptive response in humans, additional studies are needed to
conﬁrm these ﬁndings and determine whether enhancement of HIR2
will open the door to new cardioprotective strategies.
7. Cardiac autophagy and aging
There is considerable evidence from preclinical studies that aging is
associated with diminished autophagy [119]. As noted earlier, there is
evidence to suggest that genetic attenuation of autophagy induces
changes in animals that resemble those seen with advanced age. Like-
wise, stimulation of autophagy via caloric restriction, Sirtuin-1 activa-
tion, inhibition of insulin and insulin-like growth factor signaling and
the administration of rapamycin and spermidine have all been reported
to increase life span [50,120–123]. Interestingly, one of the key anti-
aging interventions that extends life span inmost animals tested is calo-
ric restriction, the most potent physiological inducer of autophagy
[124]. Despite these observations, very little is known about age-
related changes in autophagy in the human heart.
To begin to address this question, we increased the sample size in
the original Jahania study [116] from 19 patients to 38 [125]. In this co-
hort of patients, the average age was 62 years and ranged between 33
and 87 years [Table 1]. Right atrial biopsies were obtained as before
and lipidation of the autophagy protein LC3 (conversion from LC3-I to
LC3-II) wasmonitored by immunoblotting. The LC3 Index was calculat-
ed by dividing the LC3-II/I ratio after CPB by the ratio before CPB initia-
tion.We used the LC3 Index tomeasure time-dependent changes in the
synthesis of LC3-I, conversion to LC3-II, and lysosomal degradation of
LC3-II. We also used the index as a marker of autophagic ﬂux during
CPB. The analysis was completed on 38 biopsies before CPB and 37 biop-
sies after CPB. Consistent with our previous report [116], cardiac stress
in the setting of heart surgery with CPB was associated with signiﬁcant
autophagic ﬂux. When the data was examined in the context of age, we
observed that increasing age was associated with a higher LC3 Index.
We also assessed changes in the LC3-II/I ratio as a function of time and
found that for each 10 minute increase in ischemic time, the LC3 Index
increased by 3%. Although ischemic time was associated with the LC3
Index, age did not affect this relationship. The decrease in LC3-I during
CPB is attributed to inadequate production of LC3-I, inadequate
delipidation of LC3-II, and/or increased LC3 lipidation. The increase in
LC3-II may be due to increased LC3 lipidation, impaired delipidation of
LC3-II, and/or impaired lysosomal clearance of LC3-II. Delipidation of
LC3-II is mediated by Atg4, whose enzymatic activity is inhibited by
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regarded as a controversial measure of autophagy, time-dependent
changes in the ratio (LC3 Index) in biopsies from the same patient
may be informative. Interestingly, the increase in the LC3 Index suggests
that older patients are still capable of mounting a robust autophagic re-
sponse. This differs fromwhat has been reported in aged animal studies
[119]. However, these patients were deemed to be vigorous enough to
withstand the stresses of cardiac surgery based on preoperative screen-
ing including relatively normal preoperative ventricular function. The
ﬁndings suggest that in this cohort of patients, ischemic stress can elicit
a robust autophagic response that is age independent. If conﬁrmed in
future studies, the homeostatic intracellular repair response could be-
come an important therapeutic target regardless of age.8. Impact of diabetes on cardiac autophagy
There is preclinical evidence that autophagy is compromised in ani-
mals with features of metabolic syndrome (MetS), a condition associat-
ed with obesity, dyslipidemia, elevated fasting blood glucose levels and
insulin resistance [126]. Likewise, type 2 diabetes (T2DM) has been as-
sociated with impaired autophagy in various animal models [113]. This
is not surprising given that MetS and type 2 diabetes both represent ex-
cess nutrient conditions with active mTOR and suppression of autopha-
gy. The nutrient sensor mTOR participates in the dynamic regulation of
autophagy: it potently suppresses autophagy through phosphorylation
of an inhibitory site on ULK1. During nutrient deprivation, mTOR is
inactivated by AMPK. As autophagicﬂux proceeds,mTOR,which is asso-
ciated with the lysosome, is reactivated by leucine generated by lyso-
somal degradation, and suppresses further autophagy, closing the
feedback loop. Dysregulation of mTOR can arise if autophagic ﬂux or ly-
sosomal function is impaired.
Very little is known about the effects of diabetes on the HIR2 in
humans. Using the Jahania expanded data set (n = 38 patients); we
asked the question whether HIR2 is impaired in patients with poorly
controlled diabetes.We used the Society of Thoracic Surgeons' database
to identify the patientswith T2DM(n=15) andHbA1c levels as amark-
er of diabetic control: patient HbA1c levels greater than 7% prior to sur-
gery were deemed to represent a poorly controlled subset. As before,
the HIR2 was assessed by measuring Beclin-1, LC3-I, LC3-II, and p62 in
the right atrial biopsies before initiation and after weaning from CPB.
The pre-post difference in p62 (Δp62)was used to assess autophagic ac-
tivity during surgery. The demographics of the cardiac surgery patients
and their diabetic status are shown in Table 1.
Altogether, 23 nondiabetic and 15 diabetic patients were evaluated
[Table 2]. The average HbA1c levels in the nondiabetic and diabetic pa-
tients were 5.6% and 8.0%, respectively. Ten of the diabetic patients
had HbA1c levels greater than 7%. Consistent with the original study
[116], heart surgery with CPB was associated with a marked decreaseTable 2






Age (years) 61 ± 14 63 ± 12 p N 0.2
Males (%) 87% 87% p N 0.2
BMI (kg/m2) 30 ± 6.5 32 ± 5.5 p N 0.2
Dyslipidemic (%) 70% 93% p = 0.05
HbA1c (mean %) 5.6 ± 0.44 8.0 ± 2.1 p = 0.0005
Previous MI (%) 39% 40% p N 0.2
Ejection fraction (%) 52 ± 10 54 ± 6.0 p N 0.2
Aortic cross-clamp time (min) 115 ± 42 99 ± 35 p N 0.2









8%in Beclin-1 and p62 [Fig. 3]. Δp62 also correlated with ΔBeclin-1,
ΔLC3-I andΔLC3-II. These ﬁndingswere interpreted to indicate a robust
autophagic response. While there was no relationship between the
HbA1c value and Δp62 in the non-diabetic patient cohort, in the T2DM
patients, there was a signiﬁcant inverse relationship between Δp62
and HbA1c [Fig. 4]. Interestingly the autophagic response in all diabetic
patients was comparable to the non-diabetics. However, among dia-
betics with poor glycemic control (HgbA1c N 7.0%), the autophagic re-
sponse was impaired. These ﬁndings support the concept that T2DM
adversely affects adaptive autophagy in the humanheart and implicates
a pathophysiological process that may be involved in the increased sus-
ceptibility of diabetic patients to myocardial ischemia.
9. Clinical implications
Ischemic preconditioning is widely studied as a powerful cardio-
protective intervention [127,128]. We previously showed that ischemic
preconditioning and pharmacologic preconditioning depend upon au-
tophagy for their ability to protect the heart from ischemia/reperfusion
injury [129–131], and autophagy targeting mitochondria is speciﬁcally
required for protection [132]. Other cardioprotective interventions
such as chloramphenicol [133], caloric restriction [134] simvastatin
[135], SAHA [136], and rapamycin [136,137] also involve autophagy.
Early work by Vatner's group showed that autophagy was upregulated
in hibernating myocardium, and that autophagy markers did not colo-
calize with apoptosis, suggesting that autophagy was a protective
response to ischemic stress [138]. One study using Beclin-1 haploin-
sufﬁcient mice concluded that autophagy was protective during
ischemia but deleterious during reperfusion, because Beclin-1 was up-
regulated during reperfusion and Beclin-1+/−mice had smaller infarcts
[139]. In contrast, chloramphenicol administered to pigs potently up-
regulated Beclin-1 yet reduced infarct size substantially, even when
given at reperfusion [133]. The confusion surrounding Beclin-1 may be
due to its roles in promoting canonical and non-canonical autophagy
as well as regulating lysosome autophagosome fusion, where, in part-
nership with Rubicon, it can impede ﬂux [140]. In the stressed heart, it
appears that Beclin-1 haploinsufﬁciency alleviates the impediment
to ﬂux, resulting in accelerated autophagy [141]. Selective autophagy
targeting mitochondria is also important for cardiac homeostasis.
Ischemia/reperfusion injury is exacerbated by deletion of Parkin or
PINK1 [142,143], and we have demonstrated Parkin's role in ischemic
preconditioning [132].
The role of autophagy in pressure overload hypertrophy and heart
failure has been less clear. Loss of autophagy (inducible deletion of
Atg5 in adultmice) results in heart failure [144], and upregulation of au-
tophagy by exercise or Atg7 overexpression ameliorates desmin-related
cardiomyopathy [145]. Cardiac-speciﬁc (constitutive) deletion of Atg5
exacerbated pressure overload hypertrophy [144]. However, Beclin-1
haploinsufﬁcient mice exhibited some protection from pressure-
overload hypertrophy, leading the authors to conclude that autophagy
was maladaptive [146]. However, if re-interpreted in light of Diwan's
ﬁndings that the Beclin-1+/− mice have accelerated autophagic ﬂux
[141], then the two studies are not contradictory. Rapamycin has also
been shown to ameliorate heart failure in chronic models [147]. Taken
together, these observations support a beneﬁcial role for autophagy in
the heart.
Cardiac dysfunction is exacerbated by conditions in which
autophagy/mitophagy is impaired. Obesity [2] and diabetes [148] am-
plify mTOR signaling cascades that suppress autophagy. High fat diets
are associatedwith impaired autophagy [2] andmitochondrial dysfunc-
tion [149,150], and are well known to increase myocardial ischemia/
reperfusion injury [151,152].
Autophagy may not always be good for the heart. Autophagic ma-
chinery supports replication and dissemination of coxsackievirus B, a
virus responsible for myocarditis and heart failure [153,154]. Excessive
autophagy may also contribute to doxorubicin-mediated cardiac injury
Fig. 3.Correlations between p62 and othermarkers of autophagy. Thedelta value refers to thedifference in abundance (detected bywestern blotting) frombeginning of aortic cross-clamp
to end. All values normalized to actin levels. A larger delta value reﬂects greater autophagic ﬂux. p b 0.0001 for all correlations.
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agy [78,157–159]. Doxorubicin toxicity was exacerbated by deletion of
Nrf2, a transcriptional regulator of autophagy and mitochondrial bio-















Fig. 4. Relationship between Δp62 and HbA1c in diabetic cardiac surgery patients.
Delta p62 frombeginning to end of cross-clampwasdetermined bywestern blot after nor-
malizing to actin, and plotted against HgbA1c values in the diabetic patients (p = 0.030,
n = 15).Despite the wide variety of diseases affected by autophagy and the
implications for modulating these diseases, we know very little about
the function of autophagy in humans. The translation of the clinical
and pre-clinical ﬁndings described above into clinical studies is just be-
ginning. Currently, only 37 phase I/II clinical trials that use the keyword
“autophagy” are listed on ClinicalTrials.gov. Themajority of these (29 of
37) are in the ﬁeld of oncology; only one is in cardiac disease. Despite
the limited knowledge of how autophagy affects the human heart, ani-
mal data and our preliminary human studies suggest that autophagy is
activated during the process of ischemia–reperfusion. Although there
are no approved therapies to treat I/R injury, modulation of autophagy,
a process that protects cells under stress, holds tremendous promise for
ameliorating age-related cardiac pathologies.
What happened when autophagy didn't:
A mito decayed and leaked DNA
Plus cytochrome c and 8-oxo-dG
The inﬂammasome blew
And the apoptosome too
And the cell had a very bad day.
Roberta A. Gottlieb
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